Cargando…
Outcomes Associated With Use of a Kinin B2 Receptor Antagonist Among Patients With COVID-19
This case-control study examines the association between receipt of the bradykinin 2 (B2) receptor antagonist icatibant and improved oxygenation in patients with coronavirus disease 2019 (COVID-19).
Autores principales: | van de Veerdonk, Frank L., Kouijzer, Ilse J. E., de Nooijer, Aline H., van der Hoeven, Hans G., Maas, Coen, Netea, Mihai G., Brüggemann, Roger J. M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Medical Association
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7426743/ https://www.ncbi.nlm.nih.gov/pubmed/32789513 http://dx.doi.org/10.1001/jamanetworkopen.2020.17708 |
Ejemplares similares
-
Kallikrein-kinin blockade in patients with COVID-19 to prevent acute respiratory distress syndrome
por: van de Veerdonk, Frank L, et al.
Publicado: (2020) -
A higher BMI is not associated with a different immune response and disease course in critically ill COVID-19 patients
por: Kooistra, Emma J., et al.
Publicado: (2021) -
Tibial post fracture pain is reduced in kinin receptors deficient mice and blunted by kinin receptor antagonists
por: Minville, Vincent, et al.
Publicado: (2019) -
Anakinra treatment in critically ill COVID-19 patients: a prospective cohort study
por: Kooistra, Emma J., et al.
Publicado: (2020) -
Pharmacologic Targets and Prototype Therapeutics in the Kallikrein-Kinin System: Bradykinin Receptor Agonists or Antagonists
por: Sharma, J. N., et al.
Publicado: (2006)